Drug Profile
Odevixibat - Albireo Pharma
Alternative Names: A-4250; Bylvay; Odevixibat sesquihydrate - Alberio Pharma; ODEVIXIBAT1Latest Information Update: 13 Feb 2024
Price :
$50
*
At a glance
- Originator Albireo AB
- Developer Albireo AB; Albireo Pharma
- Class Acetamides; Butyric acids; Hepatoprotectants; Small molecules; Sulfones; Thiazepines
- Mechanism of Action Sodium-bile acid cotransporter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Alagille syndrome; Intrahepatic cholestasis
- Phase III Biliary atresia
- Phase II Cholestasis
- Discontinued Non-alcoholic steatohepatitis; Primary biliary cirrhosis; Primary sclerosing cholangitis
Most Recent Events
- 08 Feb 2024 Ipsen anticipates regulatory approval for Alagille syndrome in the EU, in the second half of 2024
- 08 Jan 2024 Updated efficacy and safety data from a phase III PEDFIC 1 and PEDFIC 2 trial in Intrahepatic cholestasis presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases
- 30 Nov 2023 Discontinued - Phase-I for Primary sclerosing cholangitis in USA (PO) before November 2023 (Ipsen pipeline, November 2023)